There is no comparison between them. The relative market caps should be your first clue.
BIT225 is a drug which Biotron hope will be used in conjunction with current and future HIV/HCV regimes.
The other is a ddRNAi platform company who are targeting HCV in the first instance. ddRNAi has implications for single treatment cures for genetic disease, viruses and cancers.
The recent shareholder update from Biotron explains their position clearly.
Happy researching.
bit v blt, page-2
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BIT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
3.0¢ |
Change
-0.003(9.09%) |
Mkt cap ! $27.06M | |||
| Open | High | Low | Value | Volume |
| 3.3¢ | 3.4¢ | 3.0¢ | $32.26K | 1.016M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 720804 | 3.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 3.1¢ | 30000 | 1 |
View Market Depth
| Last trade - 16.10pm 25/07/2024 (20 minute delay) ? |
| BIT (ASX) Chart |